DOW vs STRO · P/E 74, rev $42.96B vs rev $62.0M
Dow Inc (DOW) versus Sutro Biopharma (STRO) — a side-by-side from cached financials, not a winner call.
Dow Inc (DOW) is a chemicals company listed on US.
Sutro Biopharma (STRO) is a biotechnology company listed on NASDAQ.
Latest reported DOW revenue for 2024-12-31 was $42.96B. Net income was $1.20B. Revenue was down 3.7% from 2023-12-31 to 2024-12-31. DOW currently screens at market cap $20.89B and trailing P/E 73.9.
Latest reported STRO revenue for 2024-12-31 was $62.0M. Net income was -$227.5M. Revenue was down 59.6% from 2023-12-31 to 2024-12-31. STRO currently screens at market cap $470.8M.
DOW currently screens at market cap $20.89B and trailing P/E 73.9. STRO currently screens at market cap $470.8M.
Not investment advice. Open the DOW and STRO stock pages for the full models.
Not investment advice.